Evogene Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Ofer Haviv

Algemeen directeur

US$401.0k

Totale compensatie

Percentage CEO-salaris	97.3%
Dienstverband CEO	19.9yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	5.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ofer Haviv's beloning veranderd ten opzichte van Evogene's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$20m
Mar 31 2024	n/a	n/a	-US$21m
Dec 31 2023	US$401k	US$390k	-US$24m
Sep 30 2023	n/a	n/a	-US$20m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$25m
Dec 31 2022	US$464k	US$415k	-US$27m
Sep 30 2022	n/a	n/a	-US$31m
Jun 30 2022	n/a	n/a	-US$32m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	US$530k	US$420k	-US$28m
Sep 30 2021	n/a	n/a	-US$29m
Jun 30 2021	n/a	n/a	-US$26m
Mar 31 2021	n/a	n/a	-US$24m
Dec 31 2020	US$592k	US$367k	-US$23m
Sep 30 2020	n/a	n/a	-US$21m
Jun 30 2020	n/a	n/a	-US$21m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$538k	US$366k	-US$18m
Sep 30 2019	n/a	n/a	-US$18m
Jun 30 2019	n/a	n/a	-US$18m
Mar 31 2019	n/a	n/a	-US$19m
Dec 31 2018	US$517k	US$324k	-US$21m
Sep 30 2018	n/a	n/a	-US$21m
Jun 30 2018	n/a	n/a	-US$21m
Mar 31 2018	n/a	n/a	-US$21m
Dec 31 2017	US$649k	US$359k	-US$21m

Compensatie versus markt: De totale vergoeding ($USD 401.00K ) Ofer } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de IL markt ($USD 426.04K ).

Compensatie versus inkomsten: De vergoeding van Ofer is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ofer Haviv (58 yo)

19.9yrs

Tenure

US$401,000

Compensatie

Mr. Ofer Haviv, CPA, served as Interim Chief Executive Officer of Lavie Bio Ltd. since January 2023. He has been Chief Executive Officer and President of Evogene Limited since December 2004 and served as i...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ofer Haviv	CEO & President	19.9yrs	US$401.00k	geen gegevens
Brian Ember	Chief Executive Officer of AgPlenus Ltd	2.9yrs	US$456.00k	geen gegevens
Elran Haber	Chief Executive Officer of Biomica Ltd	6.8yrs	US$339.00k	0% ₪ 0
Amit Noam	Chief Executive Officer of Lavie Bio Ltd.	1.6yrs	US$606.00k	geen gegevens
Yaron Eldad	Chief Financial Officer	2.6yrs	geen gegevens	0% ₪ 0
Rachel Gerber	Head of Investor Relations	1.4yrs	geen gegevens	geen gegevens
Sassi Masliah	Vice President of Corporate Development	2.8yrs	US$304.00k	0% ₪ 0
Liat Wejgman	Vice President of Human Resources	2.8yrs	geen gegevens	geen gegevens
Eyal Ronen	Executive Vice President of Business Development	2.4yrs	geen gegevens	0% ₪ 0
Yoash Zohar	Chief Executive Officer of Casterra Ag Ltd.	less than a year	geen gegevens	geen gegevens
Dan Gelvan	Chief Executive Officer of Ag Plenus Ltd.	less than a year	geen gegevens	geen gegevens
Russ Putland	Vice President of Commercial of Lavie Bio Ltd.	no data	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van EVGN wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Dan Falk	Independent Director	3yrs	geen gegevens	0% ₪ 0
Nir Nimrodi	Independent Director	2yrs	geen gegevens	0% ₪ 0
Leon Recanati	Independent Director	19.5yrs	geen gegevens	1.56% ₪ 590.9k
Sarit Weiss-Firon	Independent Chairperson of the Board	8.3yrs	geen gegevens	0% ₪ 0
Oded Shoseyov	Independent Director	6yrs	geen gegevens	0% ₪ 0
Adrian Percy	Independent Director	5.8yrs	geen gegevens	0% ₪ 0
Eran Segal	Scientific Advisor	2.8yrs	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van EVGN wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Evogene Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Evogene Ltd. Announces Executive Changes

Evogene Ltd., Annual General Meeting, Jun 06, 2024

Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024

Evogene Ltd., Annual General Meeting, May 11, 2023

Evogene Ltd., Annual General Meeting, Sep 08, 2022

Eyal Ronen Joins as Executive Vice President of Business Development of Evogene Ltd., Effective as of June 12, 2022

Recent updates

Evogene Ltd. to Report Q3, 2024 Results on Nov 21, 2024

Evogene Ltd. Announces Executive Changes

Evogene Ltd. to Report Q2, 2024 Results on Aug 22, 2024

Evogene Ltd. to Report Q1, 2024 Results on May 23, 2024

Evogene Ltd., Annual General Meeting, Jun 06, 2024

Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $7.3 million.

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Full year 2023 earnings released: US$0.52 loss per share (vs US$0.65 loss in FY 2022)

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Evogene Ltd. to Report Q4, 2023 Results on Mar 07, 2024

Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024

New major risk - Share price stability

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.081 loss per share (vs US$0.16 loss in 3Q 2022)

Evogene Ltd. to Report Q3, 2023 Results on Nov 15, 2023

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Second quarter 2023 earnings released: US$0.17 loss per share (vs US$0.21 loss in 2Q 2022)

Evogene Ltd. to Report Q2, 2023 Results on Aug 17, 2023

Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein Discovery

Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS Program

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

New minor risk - Share price stability

Evogene Ltd., Annual General Meeting, May 11, 2023

Evogene Ltd. to Report Q1, 2023 Results on May 18, 2023

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Full year 2022 earnings released: US$0.65 loss per share (vs US$0.69 loss in FY 2021)

Third quarter 2022 earnings released: US$0.16 loss per share (vs US$0.19 loss in 3Q 2021)

Evogene Ltd. to Report Q3, 2022 Results on Nov 17, 2022

Here's Why We're Watching Evogene's (TLV:EVGN) Cash Burn Situation

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.15 loss in 2Q 2021)

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Evogene Ltd., Annual General Meeting, Sep 08, 2022

Evogene Ltd. to Report Q2, 2022 Results on Aug 31, 2022

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Eyal Ronen Joins as Executive Vice President of Business Development of Evogene Ltd., Effective as of June 12, 2022

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.17 loss in 1Q 2021)

Evogene Ltd. to Report Q1, 2022 Results on May 26, 2022

High number of new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Evogene Ltd. to Report Q4, 2021 Results on Mar 10, 2022

High number of new directors

Evogene Ltd. Announces Executive Changes

Chief Executive Officer of AgPlenus Ltd. Douglas Eisner has left the company

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2020)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.17 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 1Q 2020)

Here's Why We're Not Too Worried About Evogene's (TLV:EVGN) Cash Burn Situation

Full year 2020 earnings released: US$0.83 loss per share (vs US$0.70 loss in FY 2019)

Evogene Ltd. to Report Q4, 2020 Results on Mar 03, 2021

New 90-day high: ₪25.00

Companies Like Evogene (TLV:EVGN) Are In A Position To Invest In Growth

New 90-day high: ₪19.10

New 90-day high: ₪14.94

What Can We Make Of Evogene's (TLV:EVGN) CEO Compensation?

Third quarter 2020 earnings released: US$0.18 loss per share

Evogene Ltd. to Report Q3, 2020 Results on Nov 18, 2020

First half earnings released

New 90-day high - ₪9.46

New 90-day high - ₪5.63

New 90-day high - ₪4.17

First half earnings released

Evogene Ltd. to Report Q2, 2020 Results on Aug 05, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam